



Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

1/21/2022

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Friday, January 28, 2022 at 11:00 a.m. ET.

A live webcast of the presentation will be available through the Investor Relations section of Geron's website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMPactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220121005027/en/): <https://www.businesswire.com/news/home/20220121005027/en/>

Olivia Bloom
Chief Financial Officer
investor@geron.com
media@geron.com

Source: Geron Corporation